August 22, 2011
The current study assessed the effects of particular antiretroviral therapies (ART) on lipids among children with HIV.
The study patients received care from two hospitals in London during 1995-2007; 449 children were followed for a median 4.5 years.
Using mixed-effects models adjusted for confounders, investigators screened the children for lipid-lowering management according to American Academy of Pediatric criteria (low-density lipoprotein cholesterol above 190 mg/dL or 4.9 mmol/L for no known cardiovascular disease risk factors; LDL above 160 mg/dL or 4.1 mmol/L for two or more risk factors).
Journal of Acquired Immune Deficiency Syndromes
08.15.2011; Vol. 57; No. 5: P. 404-412; Margaret P. Rhoads, BA, MBBS; Julie Lanigan, RD; Colette J. Smith, PhD; E.G. Hermione Lyall, MBBS, MD
No comments have been made.